Skip to main content
Premium Trial:

Request an Annual Quote

Epoch Biosciences, U.S. Genomics, Celera, Paracel

Premium

Epoch Biosciences has made available 300 assays targeting SNPs linked with certain cancer populations. These validated real-time PCR assays, identified by the National Cancer Institute, are based on Epoch’s MGB Eclipse probe systems, and were developed with members of NCI’s Cancer Genome Anatomy Project.

Epoch claims that each assay has been functionally tested using a panel of 102 human genomic DNAs specified by the NCI and “verified to yield 100 percent concordance” with genotype calls made by sequencing. Epoch is selling the assays in three order sizes — 500, 1,500, and 5,000 reactions. They can be run on any existing RT-PCR instrument using commercially available PCR reagents, Epoch said.


U.S. Genomics has launched its Trilogy platform for direct detection and quantitation of individual DNA, RNA, and protein molecules without the need for amplification. The company said the first applications will enable researchers to measure microRNA and siRNA and screen samples against a panel of “all known” small RNAs. Trilogy can also validate and characterize specific microRNAs and siRNAs of interest, U.S. Genomics said.


Celera subsidiary Paracel has released version 2.0 of AGENT, or Automated Genotyping Tool, which is targeted at research labs. The software is designed to increase the efficiency of genotyping and mutation discovery by handling trace file datasets. The software uses TraceTuner MX algorithms for base calling and quality value assignment. TraceTuner MX is optimized for heterozygous and mixed bases and can distinguish between noise peaks and low-level mixed bases in pooled samples and viral samples.

 

Filed under

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.